Abstract
Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
Keywords: Progenitor cell, differentiation, paracrine factors, cell delivery, tissue engineering, myocardial infarction
Current Stem Cell Research & Therapy
Title: Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Volume: 4 Issue: 3
Author(s): David Simpson and Samuel C. Dudley Jr.
Affiliation:
Keywords: Progenitor cell, differentiation, paracrine factors, cell delivery, tissue engineering, myocardial infarction
Abstract: Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.
Export Options
About this article
Cite this article as:
Simpson David and Dudley Jr. C. Samuel, Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?, Current Stem Cell Research & Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488809789057437
DOI https://dx.doi.org/10.2174/157488809789057437 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
Current Cardiology Reviews The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Metformin Beyond Diabetes: New Life for an Old Drug
Current Diabetes Reviews Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease
Current Neurovascular Research (Pro)renin Receptor: Pathological Role and Therapeutic Potential in Primary Hypertension
Current Hypertension Reviews Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer
Current Pharmaceutical Design Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets Editorial [Hot Topic: Drug Metabolisms Associated with Human Microbiome (Guest Editor: Chun-Ming Huang) ]
Current Drug Metabolism Evaluation of Clinical Efficacy of Fasudil for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery A Transcriptomics Study to Elucidate the Toxicological Mechanism of Methylmercury Chloride in a Human Stem Cell Based In Vitro Test
Current Medicinal Chemistry Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Potential of Stem/Progenitor Cells in Human Skeletal Muscle for Cardiovascular Regeneration
Current Stem Cell Research & Therapy Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy MicroRNAs in the Management of Heart Failure
Current Medicinal Chemistry High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives
Current Cardiology Reviews